Research Article

The Medical Necessity for Medicinal Cannabis: Prospective, Observational Study Evaluating the Treatment in Cancer Patients on Supportive or Palliative Care

Table 3

Association between patient characteristics with cancer-related symptoms among long-term cannabis users.

No. of patientsSymptom score 1st interview (median, range)Symptom score 2nd interview (median, range)Difference in symptoms score between groups, before treatmentDifference in symptoms score between groups, after treatment value

All patients10613 (4–30)7 (0–20)<0.001
Age:
 ≤30 years
 31–70 years
 ≥71 years
19
58
29
11 (6–30)
13 (4–24)
13 (6–22)
4 (1–17)
7 (0–20)
8 (1–19)
0.880.06<0.001
<0.001
<0.001
Gender:
 Male6312 (6–30)7 (0–20) 0.95 0.98 <0.001
 Female4314 (4–21)7 (1–19)
Oncology treatment aim:
 Curative/adjuvant
 Palliative
57
49
11 (6–22)
13 (4–30)
5 (0–18)
7 (0–20)
0.150.052<0.001
<0.001
Chemotherapy last 3 months:
 Yes
 No
79
27
13 (4–30)
11 (6–24)
7 (0–20)
7 (0–18)
0.090.89<0.001
<0.001
Radiotherapy last 3 months:
 Yes
 No
22
84
15 (6–24)
12 (4–30)
9 (1–19)
7 (0–20)
0.030.2<0.001
<0.001
Past cannabis smoking:
 Yes
 No
29
77
12 (6–30)
13 (4–22)
5 (1–20)
8 (0–19)
0.30.057<0.001
<0.001
Cigarette smoking:
 Yes
 No
 In the past
25
30
51
13 (4–22)
13 (6–21)
13 (6–30)
8 (1–19)
6 (0–20)
9 (0–18)
0.350.29<0.001
<0.001
<0.001
Mood disorders:
 No
 Low
 Severe
6
79
21
13 (8–20)
12 (4–24)
16 (4–30)
10 (4–16)
6 (0–20)
9 (2–19)
0.0010.06<0.001
<0.001
<0.001
Weight loss:
 Yes
 No
58
48
14 (4–30)
11 (6–20)
8 (0–19)
6 (1–20)
0.020.1<0.001
<0.001
Memory loss:
 Yes
 No
23
83
14 (6–30)
12 (4–24)
8 (0–19)
7 (0–20)
0.0490.18<0.001
<0.001
Pain:
 Neuropathic
 Nociceptive
24
56
14 (6–30)
13 (6–24)
7 (2–19)
8 (0–20)
0.380.71<0.001
<0.001
Distress thermometer:
 1–4
 5–7
 8–10
34
36
36
12 (6–21)
12 (4–24)
16 (6–30)
6 (1–16)
7 (1–20)
9 (0–19)
0.0020.055<0.001
<0.001
<0.001
Symptom score:
 4–10
 11–16
 ≥17
31
53
22
8 (4–10)
13 (11–16)
20 (17–30)
4 (1–20)
7 (0–19)
12 (3–19)
<0.001<0.001
<0.001
<0.001